Local doctors question Mexico cancer treatment
Pharmaceutical giant Glaxo-Smith-Kline on Monday submitted final data supporting its application to market its cervical cancer vaccine in the united states.
Approval from the U.S. Food and Drug Administration is pending.
The vaccine is currently approved for use in more than 90 countries.
And a rival vaccine from merck and company, is already on the U.S. market.
Click here to read the full story.
||High: 89° | Low: 54°